Orphan drug designation granted to TNFerade for pancreatic cancer

GenVec was granted orphan drug designation by the FDA for its drug candidate, TNFerade for the treatment of pancreatic cancer.  TNFerade has already been granted Fast Track designation by the FDA and is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer.

TNFerade is an adenovector, or DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNF-alpha), an immune system protein with potent and well-documented anti-cancer effects, for direct injection into tumors. After administration, TNFerade stimulates the production of TNF-alpha in the tumor.

For more information call (877) 943-6832 or visit www.genvec.com.